SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
BiotechTV - News
00:00
Safety visibility and DMC findings
Marc reports 80% of patients surpassed 44 weeks with no safety signals seen by the DMC so far.
Play episode from 05:19
Transcript
